Published by Coherent Market Insights
Posted on September 15, 2021
7 min readLast updated: January 21, 2026
Personalized Cell Therapy Market, By Cell Type (Lymphocytes, Mesenchymal Stem Cell, Hematopoietic Stem Cell, and Others), by Therapeutic Area (Cardiovascular Diseases, Neurological Disorders, Inflammatory Diseases, Diabetes, and Cancer), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ XX million in 2021 and is expected to exhibit a CAGR of XX% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/204
Market Overview:
Personalized cell therapy for the treatment of different diseases like cancer and auto-immune disorders by injecting live cells directly into the body of a patient is called personalized cell therapy. It has many applications like platelet-rich concentrate, bone marrow transplants, whole blood transplants, intravenous loaded red cell injections, and even organ transplants. It is also known to be the most effective method of delivery in some patients. This type of treatment is useful in the treatment of autoimmune disorders. The procedure involves the administration of living human or animal cells into the affected part of the patient where they are grown and treated.
Key Market Drivers:
Growing need for early detection of the disease as this therapy support accurate diagnosis of disease and active monitoring of the treatment response is driving growth of the personalized cell therapy market. The growing geriatric population is increasing prevalence of the chronic disease is again fostering growth of the market. According to the World Health Organization, by 2020, the number of people aged 60 years and older will outnumber children younger than 5 years. In 2050, 80% of older people will be living in low- and middle-income countries.
The increasing launch of innovative products is augmenting growth of the market. For instance, in July 2020, the U.S. Food and Drug Administration approved Tecartus (brexucabtagene autoleucel), cell-based gene therapy for the treatment of adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded to or who have relapsed following other kinds of treatment. It is a first cell-based gene therapy approved by the FDA for the treatment of MCL.
Covid-19 Impact Analysis
The outbreak of COVID-19 impact has minimal or negligible impact on the personalized cell therapy market. This is due to the fact that infection has to increase in the need for high efficacy drugs or vaccine. Cell-based therapy is an important step during the production of vaccines or drugs. However, during the initial days of the outbreak of infection, there was a disruption in the supply chain which has ultimately led to the delay in clinical trials.
Key Takeaways:
1. The personalized cell therapy market is expected to exhibit a CAGR of XX % over the forecast period, owing to the growing partnership and agreement among key players for developing novel drugs. For instance, in October 2020, Twist Bioscience and Neogene Therapeutics announced that they have formed a broad strategic partnership to develop personalized chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies for patients with cancer.
2. North America is expected to hold a dominant position in the global market owing to the high prevalence of cancer and growing regulation for personalized cell therapy. For instance, in February 2021, the U.S. Food and Drug Administration has adopted public policies designed to reinforce cancer care’s shift toward a more effective and efficient era of personalized medicine.
Top Key Players Include In Personalized Cell Therapy Market: Cytori Therapeutics Inc., Bellicum Pharmaceuticals, Inc., Saneron CCEL Therapeutics, Inc., MolMed S.p.A., Vericel Corporation, Novartis AG, Gilead Sciences, Inc., Celgene Corporation, Bluebird Bio, Inc. and Aurora Biopharma Inc.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/204
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Personalized Cell Therapy Market will grow at 23.5% CAGR: Impact of COVID-19 on Demand and Supply of Personalized Cell Therapy appeared first on Gatorledger.
Personalized Cell Therapy Market, By Cell Type (Lymphocytes, Mesenchymal Stem Cell, Hematopoietic Stem Cell, and Others), by Therapeutic Area (Cardiovascular Diseases, Neurological Disorders, Inflammatory Diseases, Diabetes, and Cancer), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ XX million in 2021 and is expected to exhibit a CAGR of XX% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/204
Market Overview:
Personalized cell therapy for the treatment of different diseases like cancer and auto-immune disorders by injecting live cells directly into the body of a patient is called personalized cell therapy. It has many applications like platelet-rich concentrate, bone marrow transplants, whole blood transplants, intravenous loaded red cell injections, and even organ transplants. It is also known to be the most effective method of delivery in some patients. This type of treatment is useful in the treatment of autoimmune disorders. The procedure involves the administration of living human or animal cells into the affected part of the patient where they are grown and treated.
Key Market Drivers:
Growing need for early detection of the disease as this therapy support accurate diagnosis of disease and active monitoring of the treatment response is driving growth of the personalized cell therapy market. The growing geriatric population is increasing prevalence of the chronic disease is again fostering growth of the market. According to the World Health Organization, by 2020, the number of people aged 60 years and older will outnumber children younger than 5 years. In 2050, 80% of older people will be living in low- and middle-income countries.
The increasing launch of innovative products is augmenting growth of the market. For instance, in July 2020, the U.S. Food and Drug Administration approved Tecartus (brexucabtagene autoleucel), cell-based gene therapy for the treatment of adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded to or who have relapsed following other kinds of treatment. It is a first cell-based gene therapy approved by the FDA for the treatment of MCL.
Covid-19 Impact Analysis
The outbreak of COVID-19 impact has minimal or negligible impact on the personalized cell therapy market. This is due to the fact that infection has to increase in the need for high efficacy drugs or vaccine. Cell-based therapy is an important step during the production of vaccines or drugs. However, during the initial days of the outbreak of infection, there was a disruption in the supply chain which has ultimately led to the delay in clinical trials.
Key Takeaways:
1. The personalized cell therapy market is expected to exhibit a CAGR of XX % over the forecast period, owing to the growing partnership and agreement among key players for developing novel drugs. For instance, in October 2020, Twist Bioscience and Neogene Therapeutics announced that they have formed a broad strategic partnership to develop personalized chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies for patients with cancer.
2. North America is expected to hold a dominant position in the global market owing to the high prevalence of cancer and growing regulation for personalized cell therapy. For instance, in February 2021, the U.S. Food and Drug Administration has adopted public policies designed to reinforce cancer care’s shift toward a more effective and efficient era of personalized medicine.
Top Key Players Include In Personalized Cell Therapy Market: Cytori Therapeutics Inc., Bellicum Pharmaceuticals, Inc., Saneron CCEL Therapeutics, Inc., MolMed S.p.A., Vericel Corporation, Novartis AG, Gilead Sciences, Inc., Celgene Corporation, Bluebird Bio, Inc. and Aurora Biopharma Inc.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/204
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Personalized Cell Therapy Market will grow at 23.5% CAGR: Impact of COVID-19 on Demand and Supply of Personalized Cell Therapy appeared first on Gatorledger.
Explore more articles in the Research Reports category
